PDF (15.90 MB) - Boehringer Ingelheim Annual Report 2012

esearch & developmentperspectives for medical innovationCOOPERATION WITH UNIVERSITIES24Since well-trained pharmacoepidemiologistsare difficult to find, Boehringer Ingelheim findsitself in an international competition for talent.1We are actively working to address this bycommitting to long-term investment in trainingprogrammes and by working closely with anetwork with academic institutions.A network with academic partners, includingHarvard University, McGill University, Universityof Stellenbosch and Hannover MedicalSchool, has been established and collaborativeteaching programmes are now underway.31 harvard university2 mcgill university3 university of stellenbosch4 hannover medical schoolprofiles of the patients currently beingtreated with and without anticoagulanttherapy.to build high-quality analytic capabilitiesto assess the value of our productsin routine care.Subsequently, a long-term active monitoringsystem has been set up in collaborationwith Harvard Medical School,designed to collect information aboutthe use of pradaxa® and other oral anticoagulantsbased on electronic healthcaredata.To analyse data from millions of patients,appropriate technology and softwareneeds to be in place that allowsour epidemiologists to complete studiestimely, accurately and reproducibly.Boehringer Ingelheim is continuing tobuild such capabilities.Opportunities with increasingdata sourcesThe increasing availability of claimsand electronic medical record (EMR)data requires pharmaceutical companiesto ensure capabilities for expeditiouslyaccessing, analysing and interpretingreal-world data.Direct access to large claims and EMRdatabases has become a key success factorand the foundation for proactivedrug monitoring. Boehringer Ingelheimis expanding the number of strategicallyselected databases and is continuingPharmacoepidemiology – a rising field 47